LncRNA Information
ID EL0853 Name MALAT1 Aliases HCN; LINC00047; NCRNA00047; NEAT2; PRO2853; mascRNA
Species Homo sapiens Chromosome 11 Start site 65497762
End site 65506516 Chain plus Exon NO. 2
Assembly Ensembl Release 89 Class lincRNA NCBI accession NR_002819
Ensembl ENSG00000251562 Sequence


Disease
Disease Method Sample Expression pattern Dysfunction type Description PMID Source
paraspeckle disintegration Immunoprecipitation of Ribonucleoprotein Complex,knockdown HeLa cell down-regulated mutation Successful removal of MENepsilon/beta by a refined knockdown method resulted in paraspeckle disintegration. Furthermore, the reassembly of paraspeckles disassembled by transcriptional arrest appeared to be unsuccessful in the absence of MENepsilon/beta. 19188602
lung cancer knockdown human bronchial epithelial (HBE) cells up-regulated interaction Cigarette smoke extract (CSE) caused decreases of miR-217 levels and increases in lncRNA MALAT1 levels. The CSE-induced increase of MALAT1 expression was blocked by an miR-217 mimic, indicating that miR-217 negatively regulates MALAT1 expression. 26415832
breast cancer MALAT1-siRNA breast cancer tissues and cells up-regulated N/A MALAT1-siRNA inhibited breast cancer cell proliferation and cell cycle progression in vitro and in vivo; and downregulating miR-124 expression 26918449
non-small cell lung cancer Meta-analysis non-small cell lung cancer and pancreatic cancer up-regulated expression From subgroup analyses,we present evidence that lncRNA MALAT1 overexpression was an unfavorable prognostic factor for patients' overall survival in non-small cell lung cancer and pancreatic cancer, the pooled HRs (95% CI) were 1.86 (95% CI 1.27-2.73) and 1.78 (95% CI 1.30-2.44), respectively. In conclusion, lncRNA MALAT1 is a potential prognostic factor in human cancers. 26131129
pancreatic cancer Meta-analysis non-small cell lung cancer and pancreatic cancer up-regulated expression From subgroup analyses,we present evidence that lncRNA MALAT1 overexpression was an unfavorable prognostic factor for patients' overall survival in non-small cell lung cancer and pancreatic cancer, the pooled HRs (95% CI) were 1.86 (95% CI 1.27-2.73) and 1.78 (95% CI 1.30-2.44), respectively. In conclusion, lncRNA MALAT1 is a potential prognostic factor in human cancers. 26131129
cervical cancer Microarray, knockdown, RT-PCR, western blot, and immunofluorescence cervical cancer (CC) cells and tissues up-regulated expression The down-regulation of MALAT1 by shRNA in CC cells inhibited the invasion and metastasis in vitro and in vivo. MALAT1 functions to promote cervical cancer invasion and metastasis via induction of EMT, and it may be a target for the prevention and therapy of cervical cancers. 26798987
neuroblastoma microarray, qPCR etc. cell line (SK-N-SH ) down-regulated expression We identified a shorter transcriptional initiation site and found that CREB binds to the defined proximal promoter of the MALAT1 gene. The expression of the tumor marker MALAT1 ncRNA is sensitive to cell surface receptor activation by oxytocin in a neuroblastoma cell line. 20149803 LncRNADisease Lnc2Cancer
ovarian cancer microarray, qPCR etc. ovarian cancer tissue, cell lines (SKOV3, SKOV3.ip1 etc.) down-regulated N/A The qPCR results of seven lncRNAs (MALAT1, H19, UCA1, CCAT1, LOC645249, LOC100128881, and LOC100292680) were consistent with the deregulation found by microarray analysis, reflecting the reliability of the microarray data to some extent. 24379988 Lnc2Cancer
triple-negative breast cancer microarray, qPCR etc. triple-negative breast cancer tissue up-regulated expression We found that the expression levels of TCONS_l2_00003938, ENST00000460164, ENST00000425295, MALAT1 and HOTAIR were significantly higher in tumor tissues than non-tumor tissues, whereas there were no significant differences in the expression levels of the other 3 lncRNAs. Our study identified a set of lncRNAs that were consistently aberrantly expressed in TNBC, and these dysregulated lncRNAs may be involved in the development and/or progression of TNBC. 25996380 Lnc2Cancer
papillary thyroid carcinoma microarray, qPCR etc. papillary thyroid carcinoma tissue down-regulated expression Expression profiles of five lnc-RNAs (MEG3, HULC, HOTAIR, NEAT1, and MALAT-1) previously shown to be involved in cancer metastasis were detected by qPCR in 5 pairs of papillary thyroid cancer and 11 matched lymph node metastatic tissues. Among the five, MEG3 showed significant down-expression. Overexpression of MEG3 inhibits thyroid cancer cell migration and invasion. 25997963 Lnc2Cancer
neuroblastoma microarray, qPCR, knockdown etc. cell lines (BE(2)-C, CHP134) up-regulated N/A Here we demonstrated that N-Myc up-regulated the expression of JMJD1A in N-Myc oncogene-amplified human neuroblastoma cells by directly binding to the JMJD1A gene promoter. Affymetrix microarray studies revealed that the gene second most significantly up-regulated by JMJD1A was MALAT1. Consistent with this finding, RT-PCR and chromatin immunoprecipitation assays showed that JMJD1A bound to the MALAT1 gene promoter and demethylated histone H3K9 at the MALAT1 gene promoter. 24742640 Lnc2Cancer
colon cancer microarray, qPCR, knockdown etc. blood, cell lines (SW480 and SW620) up-regulated regulation The stimulation of colon cancer progression by TADC-derived CCL5 was associated with the up-regulation of non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1), which subsequently increased the expression of Snail. Blocking MALAT-1 significantly decreased the TADC-conditioned medium and CCL5-mediated migration and invasion by decreasing the enhancement of Snail, suggesting that the MALAT-1/Snail pathway plays a critical role in TADC-mediated cancer progression 25546229 Lnc2Cancer
colorectal cancer microarray, qPCR, Western blot etc. CRC tissue, cell lines (HCT116, SW480, SW620, LoVo, CaCo-2 etc.) up-regulated regulation In the present study, we found that MALAT1 was up-regulated in human primary CRC tissues with lymph node metastasis. Knockdown of MALAT1 inhibited CRC tumor growth and metastasis. MALAT1 regulated at least 243 genes in CRC cells in a genome-wide expression profiling. Among these genes, PRKA kinase anchor protein 9 (AKAP-9) was significantly up-regulated at both mRNA and protein levels. AKAP-9 was highly expressed in CRC cells with metastatic potential and human primary CRC tissues with lymph node metastasis. 25446987 Lnc2Cancer
glioma microarray, qPCR, Western blot, knockdown etc. cell line SHG139S down-regulated interaction Our results showed that downregulation of MALAT1 suppressed the expression of Sox2 and Nestin which are related to stemness, while downregulation of MALAT1 promoted the proliferation in SHG139S. Further research on the underlying mechanism showed that the effects of MALAT1 downregulation on SHG139S were through regulating ERK/MAPk signaling activity. And we also found that downregulation of MALAT1 could activate ERK/MAPK signaling and promoted proliferation in SHG139 cells. 26649728 Lnc2Cancer
liver cancer microarray, qPCR, Western blot, Luciferase reporter assay, RIP etc. liver cancer tissue, cell lines (HepG2, Bel-7402, SMMC-7721, HEK-293T etc.) differential expression regulation Mutual inhibition between YAP and SRSF1 maintains long non-coding RNA, Malat1-induced tumourigenesis in liver cancer. 24468535 LncRNADisease Lnc2Cancer
proliferative vitreoretinopathy Microarray, qRT-PCR biofluid of PVR (Proliferative VitreoRetinopathy) patients up-regulated expression MALAT1 was significantly up-regulated in the cellular and plasma fraction of peripheral blood in PVR patients. In vitro experiments revealed the role of MALAT1 in regulating RPE proliferation and migration, which is critical for ERMs formation. MALAT1 is a potential prognostic indicator and a target for the diagnosis and gene therapy for PVR diseases. 26241674
non-small-cell lung cancer microarray, qRT-PCR tumor samples from 383 NSCLC patients N/A interaction Gene expression analysis of A549 adenocarcinoma cells with differential MALAT-1 lncRNA expression demonstrated an influence on the expression of Bcl-2 and its interacting proteins. 25036876
non-small cell lung cancer N/A N/A N/A expression In NSCLC metastasizing tumors, MALAT-1 expression is three-fold higher than in non-metastasizing tumors. Furthermore, in patients with stage I disease, MALAT-1 expression is closely correlated with poor prognosis. 21550244 LncRNADisease
hepatocellular carcinoma N/A hepatocellular carcinoma (HCC) tissues up-regulated interaction N/A 26352013
breast cancer N/A breast cancer cells up-regulated N/A MALAT1 induced migration and invasion of breast cancer 26926567
hepatocelluar carcinoma N/A N/A N/A expression HCC and HPBL have clearly different patterns of gene expression, with genes IGF2, Fibronectin, DLK1, TGFb1, MALAT1 and MIG6 being over-expressed in HPBL versus HCC 17006932 LncRNADisease
lung adenocarcinoma N/A N/A N/A expression Metastasis associated lung adenocarcinoma transcript 1 is up-regulated in placenta previa increta/percreta and strongly associated with trophoblast-like cell invasion in vitro. 19690017 LncRNADisease
cancer N/A N/A N/A expression The expression of the long ncRNA MALAT1 correlates with tumor development, progression or survival in lung, liver and breast cancer. 20711585 LncRNADisease
cancer N/A N/A N/A expression MALAT1 is a highly conserved long ncRNA originally identified as a transcript overexpressed in many cancers. 20864030 LncRNADisease
osteosarcoma N/A N/A N/A expression Osteosarcoma patients' survival is significantly associated with MALAT-1 expression levels. 20951849 LncRNADisease
non-small cell lung cancer N/A N/A N/A expression Specific lncRNAs can serve as predictors of tumor outcome, as shown with the expression of the lncRNA MALAT-1 in early-stage non-small cell lung cancer. 21903344 LncRNADisease
breast cancer N/A N/A N/A regulation On a more mechanistic level, recent studies have revealed the contribution of lncRNAs as proto-oncogenes, e.g. GAGE6, as tumor suppressor genes, e.g. 鈥榩15 antisense RNA and lincP21' (36,91), as drivers of metastatic transformation, e.g. HOTAIR in breast cancer, and as regulators of alternative splicing, e.g. MALAT1 22492512 LncRNADisease
hepatocelluar carcinoma N/A N/A N/A mutation We conducted a case-control study and genotyped two SNPs, rs7763881 in HULC and rs619586 in MALAT1 Furthermore, the variant genotypes of rs619586 was associated with decreased HCC risk with a borderline significance. 22493738 LncRNADisease Lnc2Cancer
non-small cell lung cancer N/A N/A N/A expression lncRNA-associated disruption to alternative splicing has also been reported in non-small cell lung cancer by virtue of overexpression of MALAT1 22817756 LncRNADisease
small cell lung cancer N/A N/A N/A expression For other LncRNAs, specific targets have yet to be identified. This is the case of MALAT1, a LncRNA whose expression is three times higher in metastasizing early-stage non-small cell lung cancer vs. non-metastasizing tumours 22928560 LncRNADisease
breast cancer N/A N/A N/A regulation Sequesters SR splicing factors to regulate alternative splicing. 22996375 LncRNADisease
colon cancer N/A N/A N/A regulation Sequesters SR splicing factors to regulate alternative splicing. 22996375 LncRNADisease
liver cancer N/A N/A N/A regulation Sequesters SR splicing factors to regulate alternative splicing. 22996375 LncRNADisease
lung cancer N/A N/A N/A regulation Sequesters SR splicing factors to regulate alternative splicing. 22996375 LncRNADisease
osteosarcoma N/A N/A N/A regulation Sequesters SR splicing factors to regulate alternative splicing. 22996375 LncRNADisease
pancreatic cancer N/A N/A N/A regulation Sequesters SR splicing factors to regulate alternative splicing. 22996375 LncRNADisease
prostate cancer N/A N/A N/A regulation Sequesters SR splicing factors to regulate alternative splicing. 22996375 LncRNADisease
uterus cancer N/A N/A N/A regulation Sequesters SR splicing factors to regulate alternative splicing. 22996375 LncRNADisease
cancer N/A N/A N/A regulation MALAT1 (metastasis-associated lung adenocarcinoma transcript 1),another lncRNA associated with various cancers and metastasis (Ji et al. 2003; Lin et al. 2011)锛?, is found to affect the transcriptional and post-transcriptional regulation of cytoskeletal and extracellular matrix genes. 23463798 LncRNADisease
decreased myogenesis N/A N/A N/A expression The myostatin-induced inhibition of the long noncoding RNA Malat1 is associated with decreased myogenesis. 23485710 LncRNADisease
cancer N/A N/A N/A expression MALAT1 is upregulated in several cancer types and its overexpression has been linked to an increase in cell proliferation and migration in lung and colorectal cancer cells. 23660942 LncRNADisease
bladder cancer N/A N/A N/A expression Theseguilty by association studies have found numerous bladder-cancer associated lncRNAs 24006935 LncRNADisease
hepatocelluar carcinoma N/A N/A N/A expression Dysregulation and functional roles of lncRNAs in HCC 24183851 LncRNADisease
bladder cancer N/A N/A N/A regulation Oncogene 24373479 LncRNADisease
kidney cancer N/A N/A N/A regulation Oncogene 24373479 LncRNADisease
prostate cancer N/A N/A N/A regulation Putative marker 24373479 LncRNADisease
diabetes mellitus N/A N/A N/A expression In addition, MALAT1, a conserved lncRNA, was significantly upregulated in an RF/6A cell model of hyperglycemia, in the aqueous humor samples, and in fibrovascular membranes of diabetic patients. 24436191 LncRNADisease
breast cancer N/A N/A N/A regulation invasion & metastasis pancreas, colon, prostate liver, cervix, neuroblastoma osteosarcoma 24499465 LncRNADisease
lung cancer N/A N/A N/A regulation invasion & metastasis pancreas, colon, prostate liver, cervix, neuroblastoma osteosarcoma 24499465 LncRNADisease
uterus cancer N/A N/A N/A regulation invasion & metastasis pancreas, colon, prostate liver, cervix, neuroblastoma osteosarcoma 24499465 LncRNADisease
lung cancer N/A N/A N/A expression MALAT1, also known as NEAT2 (nuclear-enriched abundant transcript 2), was initially discovered as a predictive biomarker for metastasis development in lung cancer. 24667321 LncRNADisease
tumor N/A N/A N/A regulation MALAT1 plays a role in cell migration and tumor metastasis, as demonstrated by knockout of MALAT1 in lung cancer cell lines (Gutschner et al., 2013). 24721780 LncRNADisease
cancer N/A N/A N/A regulation They found that MALAT1 did not alter alternative splicing but rather actively regulated gene expression including a set of metastasis-associated genes. Consequently, MALAT1-deficient cells were impaired in migration and formed fewer tumor nodules in mouse xenograft. Antisense oligonucleotides (ASO) that block MALAT1 prevented metastasis formation after tumor implantation. 24757675 LncRNADisease
cervical cancer N/A N/A N/A expression Overexpressed MALAT1 was found in many solid tumors such as lung cancer, cervical cancer, and HCC. 24757675 LncRNADisease
hepatocelluar carcinoma N/A N/A N/A expression Overexpressed MALAT1 was found in many solid tumors such as lung cancer, cervical cancer, and HCC. 24757675 LncRNADisease
lung cancer N/A N/A N/A expression Overexpressed MALAT1 was found in many solid tumors such as lung cancer, cervical cancer, and HCC. 24757675 LncRNADisease
laryngeal squamous cell carcinoma N/A N/A N/A expression The result suggested that the MALAT1 was up-regulated in primary LSCC compared with adjacent non-cancerous tissues. 24817925 LncRNADisease
nasopharyngeal carcinoma N/A N/A N/A expression The result found that MALAT1 was most highly expressed in 5-8F cells (high rate to be tumor and metastasis), and up-regulated in CNE-2, C666-1 and HONE-1 which is higher malignant and poorly differentiated nasopharyngeal squamous cell carcinoma, while least expressed in NP69 epithelial cells of the eternal life. The data indicated that MALAT1 might be related to the metastasis and differentiation of NPC cells. 24817925 LncRNADisease
acute myocardial infarction N/A N/A N/A N/A Level of metastasis-associated lung adenocarcinoma transcript 1 was higher in patients with MI than in healthy volunteers (P<0.01); Patients with ST-segment-elevation MI had lower levels of metastasis-associated lung adenocarcinoma transcript 1 (P=0.005) when compared with patients with non-ST-segment-elevation 25035150 LncRNADisease
diabetes mellitus N/A N/A N/A N/A MALAT1 expression is significantly upregulated in the retinas of STZ-induced diabetic rats and db/db mice. MALAT1 knockdown could obviously ameliorate DR in vivo, as shown by pericyte loss, capillary degeneration, microvascular leakage, and retinal inflammation. Moreover, MALAT1 knockdown could regulate retinal endothelial cell proliferation, migration, and tube formation in vitro. The crosstalk between MALAT1 and p38 MAPK signaling pathway is involved in the regulation of endothelial cell function. 25356875 LncRNADisease
glioblastoma N/A N/A N/A N/A Extensive microRNA-mediated crosstalk between lncRNAs and mRNAs in mouse WIF1 re-expression in glioblastoma inhibits migration through attenuation of non-canonical WNT signaling by downregulating the lncRNA MALAT1. 25772239 LncRNADisease
non-small cell lung cancer qPCR etc. NSCLC tissue up-regulated expression Increased expression of the lncRNA MALAT-1 has been observed in several types of tumors, including metastatic non-small cell lung cancer. 12970751 LncRNADisease Lnc2Cancer
osteosarcoma qPCR etc. osteosarcoma tissue up-regulated N/A The expression of MALAT-1, IMPDH2, FTL and RHOA significantly correlated with response to chemotherapy. Expression of all four genes was increased in the poor responder group that are valuable markers for the prediction of osteosarcoma therapy outcome. Especially IMPDH2 and FTL are promising candidates for the stratification of osteosarcoma patients into low- and high-risk groups. Owing to their involvement in drug action these genes may further be potential targets for the modulation of drug sensitivity. 17660802 Lnc2Cancer
cervical cancer qPCR etc. cell line (CaSki) up-regulated Interaction MALAT1 was involved in cervical cancer cell growth, cell cycle progression, and invasion through the regulation of gene expression, such as caspase-3, -8, Bax, Bcl-2, and BclxL. 20213048 LncRNADisease Lnc2Cancer
lung adenocarcinoma qPCR etc. cell line (A549 ) differential expression interaction MALAT-1 is a novel class of non-coding RNA that promotes cell motility of lung adenocarcinoma cells through transcriptional and post-transcriptional regulation of motility related gene expression. 20937273 LncRNADisease Lnc2Cancer
colorectal cancer qPCR etc. CRC tissue, cell lines (SW620, SW480 etc.) differential expression N/A The 3' end of MALAT-1 is an important biological motif in the invasion and metastasis of CRC cells. 21503572 LncRNADisease Lnc2Cancer
non-small cell lung cancer qPCR etc. cell lines (A549, plat-E, HTB-58 etc.) up-regulated expression The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. 22088988 LncRNADisease Lnc2Cancer
cervical cancer qPCR etc. cell line (CaSki) down-regulated N/A Generally, we found that some of the RNA molecules (HOTAIR and MALAT1) are down-regulated while many of them (lincRNA-p21, GAS5, MEG3, ANRIL, and ncRNA-CCND1) are up-regulated and some others (TUG1, UCA1, and PANDA) not affected. The decline in the expression of HOTAIR and MALAT1 was clearly evident in BLM-treated HeLa and MCF cells. For lincRNA-p21, ncRNA-CCND1, and MEG3, a similar up-regulation pattern was obvious in both cell lines where the increase was generally more pronounced in BLM-treated cells. 22487937 LncRNADisease Lnc2Cancer
lung cancer qPCR etc. cell lines (A549, A549 MALAT1 KO, EBC-1 etc.) up-regulated regulation The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. 23243023 LncRNADisease Lnc2Cancer
prostate cancer qPCR etc. prostate cancer tissue, cell lines (22RV1, LNCAP-AI etc.) up-regulated N/A MALAT-1 was up-regulated in human prostate cancer tissues and cell lines. Higher MALAT-1 expression correlated with high Gleason score, prostate specific antigen, tumor stage and castration resistant prostate cancer. MALAT-1 down-regulation by siRNA inhibited prostate cancer cell growth, invasion and migration, and induced castration resistant prostate cancer cell cycle arrest in the G0/G1 phases. 23845456 Lnc2Cancer
non-small cell lung cancer qPCR etc. NSCLC tissue up-regulated N/A MALAT1 was shown to be detectable in the cellular fraction of peripheral human blood, showing different expression levels between cancer patients and cancer-free controls. For the discrimination of NSCLC patients from cancer-free controls a sensitivity of 56% was calculated conditional on a high specificity of 96%. The results of this study indicate that MALAT1 complies with key characteristics of diagnostic biomarkers, i.e., minimal invasiveness, high specificity, and robustness. 24313945 Lnc2Cancer
pituitary adenoma qPCR etc. pituitary adenomas tissue up-regulated expression Expression of the long non-coding RNAs MEG3, HOTAIR, and MALAT-1 in non-functioning pituitary adenomas and their relationship to tumor behavior. 24469926 LncRNADisease Lnc2Cancer
multiple myeloma qPCR etc. blood (plasma) down-regulated expression HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients. 24583225 LncRNADisease Lnc2Cancer
pancreatic ductal adenocarcinoma qPCR etc. PADC tissue, cell lines (Panc-1, Bxpc-3, HPDE6C-7 etc.) up-regulated N/A The relative level of MALAT1 was significantly higher in PDAC compared to the adjacent normal pancreatic tissues. When comparing the MALAT1 level in the cultured cell lines, remarkably higher expression of MALAT1 was found in aspc-1 PDAC cells compared with the immortal pancreatic duct epithelial cell line HPDE6c-7. Furthermore, MALAT1 expression level showed significant correlation with tumor size, tumor stage and depth of invasion. Kaplan-Meier analysis revealed that patients with higher MALAT1 expression had a poorer disease free survival. 24815433 Lnc2Cancer
cervical cancer qPCR etc. cervical cancer tissue, cell lines (HeLa, CaSki, SiHa, HCC94 etc.) up-regulated N/A In the present study, it was identified that MALAT1 expression was upregulated in cervical cancer cell lines compared with normal cervical squamous cell samples. Further study into the effect of MALAT1 on cellular phenotype revealed that MALAT1 was able to promote cell migration and proliferation. HPV correlates with MALAT1 deregulation in cervical cancer. 24932303 Lnc2Cancer
colorectal cancer qPCR etc. colorectal cancer tissue up-regulated regulation The MALAT1 levels in cancerous tissues were 2.26 times higher than those measured in noncancerous tissues, and this difference was statistically significant. Based on their expression level of MALAT1, the patients were divided into a high MALAT1 expression group and a low expression group. Patients with tumours harbouring higher expression of MALAT1 showed a significantly worse prognosis with a HR of 2.863 for DFS and 3.968 for OS. Furthermore, patients with perineural invasion demonstrated significantly worse DFS and OS than those without perineural invasion. 25031737 Lnc2Cancer
laryngeal squamous cell carcinoma qPCR etc. LSCC tissue up-regulated expression We discovered that five lncRNAs were differentially expressed between primary LSCC samples and adjacent normal tissues. Among them, three lncRNAs were up-expressed in tumor specimens, including CDKN2B-AS1, HOTAIR and MALAT1. More, two lncRNAs had significant down-expression, which were lncRNA RRP1B and SRA1. Cisplatin and paclitaxel have target function on significant lncRNAs in LSCC, which presents novel molecular targets to cure LSCC patients and also leads an orientation for developing new drugs. 25257554 Lnc2Cancer
multiple myeloma qPCR etc. Bone marrow up-regulated N/A MALAT1 was overexpressed in the newly diagnosed patients compared with post-treatment patients and healthy individuals. The expression of MALAT1 strongly correlated with disease status, and the magnitude of change in MALAT1 post-treatment had prognostic relevance. The patients with early progression had a significantly smaller change in MALAT1 after treatment. 25369863 LncRNADisease Lnc2Cancer
pancreatic cancer qPCR etc. pancreatic cancer tissue up-regulated expression Our results indicated that lncRNA MALAT1 was highly expressed in pancreatic cancer compared with adjacent non-cancerous tissues, and positively correlated with clinical stage, tumor size, lymph node metastasis, and distant metastasis in pancreatic cancer patients. Furthermore, we also found that lncRNA MALAT1 overexpression was an unfavorable prognostic factor in pancreatic cancer patients, regardless of clinical stage, tumor size, lymph node metastasis, and distant metastasis. Finally, increased lncRNA MALAT1 expression was an independent poor prognostic factor for pancreatic patients through multivariate analysis. 25481511 Lnc2Cancer
glioma qPCR etc. glioma tissue up-regulated expression LncRNA MALAT1 expression was increased in glioma tissues compared with paired adjacent brain normal tissues. Furthermore, lncRNA MALAT1 was associated significantly with WHO grade (I-II vs. III-IV; P = 0.007) and tumor size. Moreover, the level of lncRNA MALAT1 expression was markedly correlated with the glioma patients' overall survival. Multivariate analysis suggested that increased lncRNA MALAT1 expression was a poor independent prognostic predictor for glioma patients. 25613066 Lnc2Cancer
gastric cancer qPCR etc. gastric cancer tissue, cell lines(AGS, MKN45, 7901 etc.) up-regulated expression All the 8 lncRNAs were then subjected to qPCR validation using 20 pairs of GC and control tissues. Among them, HOTAIR, PVT1, H19, MALAT1, GHET1 and HULC were significantly higher in tumor tissues compared with control tissues. 26096073 Lnc2Cancer
lung cancer qPCR etc. blood down-regulated expression The expression of MALAT1 in the whole blood of lung cancer patients with metastasis was stronger compared to non-metastasis, which showed that MALAT1 promotes the tumor metastasis and additionally, the whole blood with lymph node metastasis represented a lower expression of MALAT1 compared to bone or brain metastasis. 26137228 Lnc2Cancer
breast cancer qPCR etc. breast cancer and adjacent non-cancerous specimens, cell lines (MDA-MB-231 and MDA-MB-453) down-regulated interaction We found that MALAT1 was downregulated in breast tumor cell lines and cancer tissue, and showed that knockdown of MALAT1 in breast cancer cell lines induced an epithelial-to-mesenchymal transition (EMT) program via phosphatidylinositide-3 kinase-AKT pathways. Furthermore, lower expression of MALAT1 in breast cancer patients was associated with shorter relapse-free survival 26191181 Lnc2Cancer
esophageal squamous cell carcinoma qPCR etc. ESCC tissue up-regulated expression MALAT1 expression was increased in ESCC tissue than in adjacent normal tissue samples (P< 0.001). MALAT1 level was positively related to pT stage (P= 0.01). 26406400 Lnc2Cancer
renal cancer qPCR etc. clear cell renal cell carcinoma and corresponding noncancerous tissues up-regulated interaction We found that MALAT1 exist a higher fold change (Tumor/Normal) in clear cell kidney carcinoma (KIRC) from The Cancer Genome Atlas (TCGA) Data Portal and a negative correlation with miR-200s family. We further demonstrated MALAT1 promote KIRC proliferation and metastasis through sponging miR-200s in vitro and in vivo. In addition, miR-200c can partly reverse the MALAT1's stimulation on proliferation and metastasis in KIRC. In summary we unveil a branch of the MALAT1/miR-200s/ZEB2 pathway that regulates the progression of KIRC. 26461224 Lnc2Cancer
colorectal cancer qPCR, in vitro knockdown, RIP etc. cell lines (LoVo, HCT116 ) up-regulated N/A We found that overexpression of MALAT1 could promote cell proliferation and migration in vitro, and promote tumour growth and metastasis in nude mice. In CRC, MALAT1 could bind to SFPQ, thus releasing PTBP2 from the SFPQ/PTBP2 complex. In turn, the increased SFPQ-detached PTBP2 promoted cell proliferation and migration. SFPQ critically mediated the regulatory effects of MALAT1. Moreover, in CRC tissues, MALAT1 and PTBP2 were overexpressed, both of which were associated closely with the invasion and metastasis of CRC. MALAT1 might be a potential predictor for tumour metastasis and prognosis.Furthermore, the interaction between MALAT1 and SFPQ could be a novel therapeutic target for CRC. 25025966 Lnc2Cancer
endometrial stromal sarcoma qPCR, ISH etc. ESS tissue up-regulated expression MALAT-1 gene is one of the major genes upregulated in ESS. 16441420 LncRNADisease Lnc2Cancer
cervical cancer qPCR, knockdown etc Tumor and adjacent normal tissues, cervical cancer cell lines(HeLa, CaSki) up-regulated expression MALAT1 expression is significantly increased in cervical cancer than in normal tissues. Its expression in the cancerous tissues is also significantly higher than in adjacent normal tissues. MALAT1 expression is correlated with tumor size, FIGO stage, vascular invasion and lymph nodes metastasis and is an independent predictor for overall survival of cervical cancer. When endogenous MALAT1 was knocked down, the cancer cells had significantly reduced proliferation and invasion and increased apoptosis 26400521 Lnc2Cancer
hepatocelluar carcinoma qPCR, knockdown etc. HCC tissue up-regulated expression Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. 21678027 LncRNADisease Lnc2Cancer
urothelial carcinoma of the bladder qPCR, knockdown etc. cell lines (T24, 5737) up-regulated N/A MALAT1 was upregulated in bladder urothelial carcinoma compared with matched normal urothelium (P=.008). The MALAT1 expression levels were greater in high-grade carcinomas than in low-grade carcinoma (P=.001). The MALAT1 expression levels were greater in invasive carcinoma than in noninvasive carcinoma (P=.018). MALAT1 plays an oncogenic role in urothelial carcinoma of the bladder. 23153939 Lnc2Cancer
melanoma qPCR, knockdown etc. melanoma tissue, cell line (A-375) up-regulated N/A highly expressed,can promote the metastasis of melanoma. The expression levels of UCA1 and Malat-1 lncRNAs had the potential to be prognostic indicators in metastasis of melanomas. 24892958 Lnc2Cancer
gastric cancer qPCR, knockdown etc. gastric cancer tissue, cell lines (MKN7, MKN45, MKN74, NUGC4, AZ521, AGS, KATOIII) up-regulated interaction Expression of both lncRNAs was significantly higher in cancerous tissues than in corresponding normal mucosa, and higher expression of these lncRNAs significantly correlated with peritoneal metastasis in GC patients. Elevated HOTAIR expression emerged both as an independent prognostic and risk factor for peritoneal dissemination. SiRNA knockdown of HOTAIR in GC cells significantly inhibited cell proliferation, migration and invasion, but concurrently enhanced the anoikis rate in transfetced cells. 25280565 Lnc2Cancer
clear cell renal cell carcinoma qPCR, knockdown etc. ccRCC tissue, cell line (HK-2) up-regulated expression The expression level of MALAT1 was higher in ccRCC tissues and renal cancer cells compared to adjacent non-tumor tissues and normal human proximal tubule epithelial cells HK-2. The ccRCC patients with higher MALAT1 expression had an advanced clinical features and a shorter overall survival time than those with lower MALAT1 expression. Additionally, our data indicated that knockdown expression of MALAT1 decreased renal cancer cell proliferation, migration, and invasion. 25480417 Lnc2Cancer
esophageal squamous cell carcinoma qPCR, knockdown etc. esophageal squamous cell carcinoma and adjacent nonneoplastic tissues, cell lines(TE1, KYSE30, KYSE70, KYSE150, KYSE270, KYSE410, EC9706) up-regulated expression Human esophageal carcinoma cell lines EC9706 and KYSE150 were transfected with MALAT-1 small interference RNA. Cell proliferation, migration/invasion ability, cell cycle, and apoptosis were assessed. MALAT-1 expressed higher levels in esophageal cancer tissues when compared with paired adjacent normal tissues. This high expression was associated with a decreased survival rate. MALAT-1 knockdown induced a decrease in proliferation-enhanced apoptosis, inhibited migration/invasion, and reduced colony formation and led to cell cycle arrest at the G2/M phase 26493997 Lnc2Cancer
osteosarcoma qPCR, knockdown etc. osteosarcoma tissue, cell lines (MG63, Saos-2, hFOB1.19, MNNG/HOS) up-regulated expression We observed that MALAT1 expression was up-regulated in human osteosarcoma cell lines and tissues. In vitro knockdown of MALAT1 by siRNA significantly inhibited cell proliferation and migration, and induced cell cycle arrest and apoptosis in osteosarcoma cells. In addition, MALAT1 knockdown markedly suppressed the formation of tubular network structures and caused breakage of stress fibers in osteosarcoma cell lines U2OS and MNNG/HOS. 26575981 Lnc2Cancer
non-small cell lung cancer qPCR, knockdown, Luciferase reporter assay etc. NSCLC tissue, cell lines (A549, YTLMC-9) up-regulated interaction MALAT1 is a non-coding RNA overexpressed in non-small cell lung cancer (NSCLC). TDP-43 is a ubiquitously expressed, MALAT1-binding protein implicated in cancer development. TDP-43 overexpression markedly increased MALAT1 transcript level. In summary, these findings demonstrated that MALAT1 expression by regulation of TDP-43 controls cellular growth, migration, and invasion of NSCLCs. 26265046 Lnc2Cancer
esophageal squamous cell carcinoma qPCR, Luciferase reporter assay etc. ESCC tissue, cell lines (KYSE30, KYSE150, KYSE450) up-regulated regulation In this study, we provide first evidences that a posttranscriptional regulation mechanism of MALAT1 by miR-101 and miR-217 exists in ESCC cells. This posttranscriptional silencing of MALAT1 could significantly suppress the proliferation of ESCC cells through the arrest of G2/M cell cycle, which may be due to MALAT1-mediated upregulation of P21 and P27 expression and the inhibition of B-MYB expression. 25538231 Lnc2Cancer
renal cell carcinoma qPCR, Luciferase reporter assay etc. RCC tissue up-regulated N/A Long Noncoding RNA MALAT1 Promotes Aggressive Renal Cell Carcinoma through Ezh2 and Interacts with miR-205. MALAT1 expression was higher in human RCC tissues, where it was associated with reduced patient survival. 25600645 LncRNADisease Lnc2Cancer
multiple myeloma qPCR, Luciferase reporter assay, ELISA, knockdown etc. bone marrow up-regulated expression The expression of MALAT1 was assessed by quantitative qPCR. Consistently higher expression level of MALAT1 was found in MSCs from all 25 patient samples relative to that from healthy donors. lncRNA MALAT1 directly interacted with Sp1 and LTBP3 promoter to increase expression of LTBP3 gene. The specificity and efficiency of activation were ensured by the formation of a stable complex between MALAT1 and the LTBP3 promoter, direct interaction of MALAT1 with Sp1 and recruitment of Sp1 to the promoter. 25187517 Lnc2Cancer
cervical cancer qPCR, Luciferase reporter assays, knockdown, RIP, RNA pull-down assay etc. cervical cancer tissue, cell lines (HeLa and CaSki) up-regulated interaction We found MALAT1 expression was significantly higher in radioresistant than in radiosensitive cancer cases. In addition, MALAT1 and miR-145 expression inversely changed in response to irradiation in HR-HPV+ cervical cancer cells. By using clonogenic assay and flow cytometry analysis of cell cycle distribution and apoptosis, we found CaSki and Hela cells with knockdown of MALAT1 had significantly lower colony formation, higher ratio of G2/M phase block and higher ratio of cell apoptosis. 26311052 Lnc2Cancer
lung cancer qPCR, Northern blot, etc. cell lines (H1299, H1975 etc.) differential expression N/A We first examined the decay of MALAT-1 in various cancer cells (H1299, H1975, A549, HT1080, and HeLa TO cells) by DRB chase experiments using 7SK RNA as a control. Half-lives of MALAT-1 in H1299, H1975, A549, HT1080, and HeLa TO cells were > 12, 12, 12, 12, and 9 h, respectively. MALAT-1 stabilities varied in various cancer cells. 22491206 Lnc2Cancer
fibrosarcoma qPCR, Northern blot, etc. cell line (HT1080) differential expression N/A We first examined the decay of MALAT-1 in various cancer cells (H1299, H1975, A549, HT1080, and HeLa TO cells) by DRB chase experiments using 7SK RNA as a control. Half-lives of MALAT-1 in H1299, H1975, A549, HT1080, and HeLa TO cells were > 12, 12, 12, 12, and 9 h, respectively. MALAT-1 stabilities varied in various cancer cells. 22491206 Lnc2Cancer
cervical cancer qPCR, Northern blot, etc. cell line (HeLa) differential expression N/A We first examined the decay of MALAT-1 in various cancer cells (H1299, H1975, A549, HT1080, and HeLa TO cells) by DRB chase experiments using 7SK RNA as a control. Half-lives of MALAT-1 in H1299, H1975, A549, HT1080, and HeLa TO cells were > 12, 12, 12, 12, and 9 h, respectively. MALAT-1 stabilities varied in various cancer cells. 22491206 Lnc2Cancer
hepatocelluar carcinoma qPCR, Northern blot, ISH etc. HCC tissue, cell line (CT26) up-regulated expression Quantitative analyses indicated a 6-7-fold increased RNA level in HCCs versus uninvolved liver, advancing this as a molecule of interest. 16878148 LncRNADisease Lnc2Cancer
prostate cancer qPCR, Northern bolt etc. prostate cancer tissue, cell lines (LNCap-AD, 22Rv1, PC-3, DU145, C4-2 etc.) up-regulated N/A qPCR was used to assess the PCA3 and MALAT-1 expression levels in an additional set of 10 pairs of PCa and adjacent normal tissues. Comparing the PCA3 and MALAT-1 expression levels in the 10 paired tissue samples revealed that PCA3 and MALAT-1 were highly expressed in most of the PCa tissues. Plasma lncRNAs probably exist in the form of fragments in a stable form. MD-miniRNA enters cell culture medium at measurable levels, and MD-miniRNA derived from human PCa xenografts actually enters the circulation in vivo and can be measured to distinguish xenografted mice from controls. 23726266 Lnc2Cancer
prostate cancer qPCR, RIP-Seq, knockdown, ChIP etc. cell lines (C4-2, PC-3, LNCaP) up-regulated interaction We showed that MALAT1 enhances expression of PRC2-independent target genes of EZH2 in CRPC cells in culture and patient-derived xenografts. Together, these data indicate that MALAT1 may be a crucial RNA cofactor of EZH2 and that the EZH2-MALAT1 association may provide a new avenue for development new strategies for treatment of CRPC. 26516927 Lnc2Cancer
gallbladder cancer qPCR, Western blot etc. GBC tissue, cell lines (SGC-996, NOZ) up-regulated regulation MALAT1 promotes the proliferation and metastasis of gallbladder cancer cells by activating the ERK/MAPK pathway. 24658096 LncRNADisease Lnc2Cancer
non-small cell lung cancer qPCR, Western blot etc. NSCLC tissue, cell lines (H1915) up-regulated expression We observed that the level of MALAT1 was significantly higher in brain metastasis than that of non brain metastasis samples. The level of MALAT1 was associated with patients' survival. We found that MALAT1 is increased in highly invasive subline of brain metastasis lung cancer cells. Further functional studies indicate that silencing MALAT1 inhibits highly invasive subline of brain metastasis lung cancer cell migration and metastasis by inducing epithelial-mesenchymal transition (EMT). 25217850 Lnc2Cancer
pancreatic cancer qPCR, Western blot etc. cell lines (AsPC-1, CFPAC-1) up-regulated expression In this study, our data showed that MALAT-1 could increase the proportion of pancreatic CSCs, maintain self-renewing capacity, decrease the chemosensitivity to anticancer drugs, and accelerate tumor angiogenesis in vitro. In addition, subcutaneous nude mouse xenografts revealed that MALAT-1 could promote tumorigenicity of pancreatic cancer cells in vivo. The underlying mechanisms may involve in increased expression of self-renewal related factors Sox2. 25811929 Lnc2Cancer
pancreatic cancer qPCR, Western blot, FCA etc. pancreatic cancer tissue, cell lines (BxPC-3, CFPAC-1, CAPAN-1, SW1990 etc.) up-regulated expression In the present study, our results showed that MALAT-1 expression levels were upregulated in pancreatic cancer tissues compared with adjacent noncancerous controls. Further function analysis revealed that downregulation of MALAT-1 could inhibit tumor cell proliferation and decrease cell migration and invasion in vitro. 25269958 Lnc2Cancer
gastric cancer qPCR, Western blot, knockdown etc. cell lines (SGC-7901, MKN-45, SUN-16) up-regulated N/A In this study, we found that MALAT1 was aberrantly highly expressed in GC cell lines (SGC-7901, MKN-45 and SUN-16), and induced specific distribution and over-expression of SF2/ASF in nucleolus. Knock-down of MALAT1 or SF2/ASF in SGC-7901 cells respectively induced significant arrest of cell cycle in G0/G1 phase along with a remarkable suppression of cell proliferation, and the nuclear distribution and expression of SF2/ASF was significantly impaired when MALAT1 was depleted. However, over-expression of SF2/ASF exhibited no effect on rescuing the cell proliferation suppression by MALAT1 depletion. 24857172 Lnc2Cancer
osteosarcoma qPCR, Western blot, knockdown etc. osteosarcoma tissue, cell lines (SAOS2, MG63, U2OS) up-regulated expression In our research, the MALAT1 messenger RNA (mRNA) was highly expressed in human osteosarcoma tissues, and its expression level was closely correlated with pulmonary metastasis. Knockdown of MALAT1 inhibited the proliferation and invasion of human osteosarcoma cell and suppressed its metastasis in vitro and vivo. MALAT1 might suppress the tumor growth and metastasis via PI3K/AKT signaling pathway. 25431257 Lnc2Cancer
esophageal squamous cell carcinoma qPCR, Western blot, knockdown etc. ESCC tissue, cell lines (EC109, EC9706, KYSE150, KYSE450) up-regulated expression MALAT1 was over-expressed in 46.3% of ESCC tissues, mostly in the high-stage tumor samples. Enhanced MALAT1 expression levels were positively correlated with clinical stages, primary tumor size, and lymph node metastasis. Inhibition of MALAT1 suppressed tumor proliferation in vitro and in vivo, as well as the migratory and invasive capacity.MALAT1 serves as an oncogene in ESCC, and it regulates ESCC growth by modifying the ATM-CHK2 pathway. 25613496 Lnc2Cancer
oral squamous cell carcinoma qPCR, Western blot, knockdown etc. OSCC tissue, cell lines (Tscca, Tca8113P160, Tca8113, Hep-2) up-regulated interaction We found that MALAT1 is overexpressed in OSCC tissues compared to normal oral mucosa by real-time PCR. MALAT1 served as a new prognostic factor in OSCC patients. When knockdown by small interfering RNA (siRNA) in OSCC cell lines TSCCA and Tca8113, MALAT1 was shown to be required for maintaining epithelial-mesenchymal transition (EMT) mediated cell migration and invasion. Western blot and immunofluorescence staining showed that MALAT1 knockdown significantly suppressed N-cadherin and Vimentin expression but induced E-cadherin expression in vitro. Meanwhile, both nucleus and cytoplasm levels of β-catenin and NF-B were attenuated, while elevated MALAT1 level triggered the expression of β-catenin and NF-B. More importantly, targeting MALAT1 inhibited TSCCA cell-induced xenograft tumor growth in vivo. 26522444 Lnc2Cancer
cervical cancer qPCR, Western blot, Luciferase reporter assay, knockdown, FCA etc. HR-HPV+ cervical cancer tisssue, cell lines (HeLa, CaSki, SiHa) up-regulated interaction Findings of this study confirmed higher MALAT1 expression in HR-HPV (+) cervical cancer. Knockdown of endogenous MALAT1 significantly reduced cell growth rate and invasion and increased cell apoptosis of Hela and siHa cells. Besides, knockdown of MALAT1 increased the expression of miRNA-124, while ectopic expression of miR-124 decreased MALAT1 expression. MALAT1 can indirectly modulate GRB2 expression via competing miR-124. Knockdown of GRB2 reduced cell invasion and increased cell apoptosis. In conclusion, MALAT1 can promote HR-HPV (+) cancer cell growth and invasion at least partially through the MALAT1-miR-124-RBG2 axis. 26242259 Lnc2Cancer
colorectal cancer qPCR, Western blot, Luciferase reporter assay, knockdown, RIP etc. CRC tissue, cell lines (LoVo etc.) up-regulated N/A Using in situ hybridization, we found there was higher expression of MALAT1 in the CRC than the adjacent normal colorectal tissue. We next conducted correlation analysis between MALAT1 expression and clinicopathological characteristics of CRC. A statistically significant association was observed between MALAT1 expression and extent of metastasis and invasion. In contrast to adjacent normal tissues, the MALAT1 expression in CRC tissues resected from patients with metastatic diseases was higher than those with no metastasis. 24244343 Lnc2Cancer
bladder cancer qPCR, Western blot, Luciferase reporter assay, knockdown, RIP etc. bladder cancer tissue, cell lines (T24, RT4 etc.) up-regulated N/A TGFβ1 induces malat1 expression and EMT in bladder cancer cells. malat1 overexpression is significantly correlated with poor survival in patients with bladder cancer. malat1 and E-cadherin expression is negatively correlated in vitro and in vivo. malat1 knockdown inhibits TGFβ1 induced EMT. malat1 is associated with suz12, and this association results in decrease of E-cadherin expression and increase of N-cadherin and fibronectin expression. Targeted inhibition of malat1 or suz12 suppresses the migratory and invasive properties induced by TGFβ1 We demonstrated that malat1 or suz12 knockdown inhibits tumor metastasis in animal models. 24449823 Lnc2Cancer
breast cancer qPCR, Western blot, Luciferase reporter assays etc. breast cancer patients tissues down-regulated interaction The effects of up-regulation of miR-1 were similar to that of silencing K-RAS and MALAT1 in breast cancer cells 26275461 Lnc2Cancer
nasopharyngeal carcinoma qPCR, Western blot, Luciferase reporter assays, RIP etc. NPC cell lines (5-8F, CNE-2, HONE-1, SUNE-1), NPE cell line (NP-69) up-regulated interaction We found that MALAT1 regulated radioresistance by modulating cancer stem cell (CSC) activity. Furthermore, we found that there was reciprocal repression between MALAT1 and miR-1, and slug was identified as a downstream target of miR-1. Taking these observations into consideration, we proposed that MALAT1 regulated CSC activity and radioresistance by modulating miR-1/slug axis, which indicated that MALAT1 could act as a therapeutic target for NPC patients 26482776 Lnc2Cancer
breast cancer qPCR, Western blot, Luciferase reporter assays, RIP etc. breast cancer specimens and adjacent normal breast tissue up-regulated interaction We reported that MALAT1 was upregulated in triple-negative breast cancer (TNBC) tissues. Knockdown of MALAT1 inhibited proliferation, motility, and increased apoptosis in vitro. In vivo study indicated that knockdown of MALAT1 inhibited tumor growth and metastasis. Patients with high MALAT1 expression had poorer overall survival time than those with low MALAT1 expression. In addition, our findings demonstrate a reciprocal negative control relationship between MALAT1 and miR-1: downregulation of MALAT1 increased expression of microRNA-1 (miR-1), while overexpression of miR-1 decreased MALAT1 expression. Slug was identified as a direct target of miR-1. 26676637 Lnc2Cancer
glioma qPCR, Western blot, Luciferase reporter assays, RIP, ChIP etc. glioma samples and normal brain tissues, cell lines (hCMEC/D3, ECs) up-regulated interaction Our results proved that MALAT1 expression was up-regulated in brain microvessels of human glioma and glioma endothelial cells (GECs) which were obtained by co-culturing endothelial cells with glioma cells. Functionally, knockdown of MALAT1 resulted in an impairment and increased the permeability of BTB as well as decreased the expression of ZO-1, occludin and claudin-5 in GECs. Further, there was reciprocal repression between MALAT1 and miR-140, and miR-140 mediated the effects that MALAT1 knockdown exerted. Mechanistic investigations defined that nuclear factor YA (NFYA), a CCAAT box-binding transcription factor, was a direct and functional downstream target of miR-140, which was involved in the MALAT1 knockdown induced regulation of BTB function. Furthermore, NFYA could up-regulate the promoter activities and bind to the promoters of ZO-1, occludin and claudin-5 in GECs. 26619802 Lnc2Cancer
breast cancer qPCR, Western blot, Northern blot, knockdown etc. cell lines (MB231, MCF7 etc.) up-regulated N/A Specifically, we looked for the changes of long non-coding RNA metastasis associated lung adenocarcinoma transcript 1 (MALAT-1), which is found extensively and highly expressed in several kinds of tumor cells, including breast carcinoma. It was observed that proliferation, migration and invasion of breast cells were greatly affected by high concentration E2 treatment and were not affected by low concentration E2 treatment in an ERa independent way. We found that the high concentration E2 treatment largely decreased MALAT-1 RNA level. Interestingly, MALAT-1 decreasing by knocking down showed similar effects on proliferation, migration and invasion. 24525122 Lnc2Cancer
nasopharyngeal carcinoma qPCR, Western bolt etc. cell lines (5-8F, 6-10B, CNE-1, CNE-2 etc.) up-regulated N/A MALAT1 was highly expressed in 5-8F cells with a high metastatic potential, and lowly expressed in normal nasopharyngeal epithelium cells. Overexpression of MALAT1 by RNAa suppressed the expression of E-cadherin, promoted the expression of vimentin and enhanced the proliferation, invasion, and metastasis of CNE-1 cells. 23688988 Lnc2Cancer
bladder cancer qPCR, Western bolt, Luciferase reporter assay etc. bladder cancer tissue, cell line (T24) up-regulated N/A We verified that MALAT-1 levels were upregulated in bladder cancer tissues compared with adjacent normal tissues, and MALAT-1 expression was remarkably increased in primary tumors that subsequently metastasized, when compared to those primary tumors that did not metastasize. levels. We further demonstrated that MALAT-1 promoted EMT by activating Wnt signaling in vitro. 22722759 Lnc2Cancer
esophageal squamous cell carcinoma qRT-PCR 106 paired ESCC tissues down-regulated N/A MALAT1 decreased tumor formation and improved survival 27015363
gastric cancer RNA immunoprecipitation RIP-seq gastric cancer cell lines N/A N/A suppresses the tumor suppressor PCDH10 and promotes gastric cellular migration and invasion 26871474
prostate cancer RNA-seq, qPCR etc. prostate cancer tissue up-regulated N/A Consistent with the RNA-seq results, PCA3, FR0348383 and MALAT1 overexpression was found in 80% (32/40), 72.5% (29/40), and 82.5% (33/40) of the prostate cancers respectively, whereas decreased FR0257520 expression was found in 82.5% (33/40) of the prostate cancers. 22349460 Lnc2Cancer
pre-eclampsia short interfering RNA (siRNA) placentas from the patients with preeclampsia, EG-3 trophoblast cell line down-regulated interaction Silencing of MALAT-1 in JEG-3 cells suppressed proliferation and induced cell cycle arrest at G0/G1 phase. The migration rate and the invasiveness of JEG-3 cells were suppressed when MALAT-1 was downregulated. MALAT-1 may play an important role in the regulation of proliferation, cell cycle, apoptosis, migration and invasion of trophoblast cells, and under-expression of MALAT-1 during early placentation may be involved in the pathogenesis of preeclampsia. 26722461
triple-negative breast cancer tissue microarray; immunoblotting, polymerase chain reaction, loss and gain of gene MDA-MB-231 cells up-regulated N/A N/A 26917489
 


Function (not disease relevant)
Methods Sample/condition Expression pattern Dysfunction type Description PMID Source
Depletion of MALAT1 or overexpression N/A N/A N/A MALAT1 regulates AS by modulating the levels of active SR 20797886
knockdown, siRNA human fetal osteoblastic cell line hFOB 1.19 up-regulated expression RANKL, binding to its receptor RANK, inhibited cell proliferation via MALAT1 upregulation in osteoblast cells in vitro. 25817340
N/A N/A N/A expression Biogenesis, metabolism, and functions of lncRNAs are otherwise interconnected with known pathogenic mechanisms 23791884 LncRNADisease
nuclear magnetic resonance and Förster resonance energy transfer N/A N/A mutation An m(6)A site in the lncRNA metastasis associated lung adenocarcinoma transcript 1 (MALAT1) was recently shown to induce a local change in structure that increases the accessibility of a U5-tract for recognition and binding by heterogeneous nuclear ribonucleoprotein C (HNRNPC). This m(6)A-dependent regulation of protein binding through a change in RNA structure, termed "m(6)A-switch", affects transcriptome-wide mRNA abundance and alternative splicing. The m(6)A-modified hairpin has a predisposed conformation that resembles the hairpin conformation in the RNA-HNRNPC complex more closely than the unmodified hairpin. 26343757
TaqMan gene expression assays, QPCR human TK6 (p53 positive) and WTK1 (p53 negative) cells up-regulated interaction The lncRNA MALAT1 and SOX2OT were induced in both TK6 and WTK1 cells 23698766
 


Interaction
Interaction target Level of interaction Type of interaction Description PMID Source
CREB DNA-TF regulation We identified a shorter transcriptional initiation site and found that CREB binds to the defined proximal promoter of the MALAT1 gene. The expression of the tumor marker MALAT1 ncRNA is sensitive to cell surface receptor activation by oxytocin in a neuroblastoma cell line. 20149803 LncRNADisease
SR RNA-Protein binding MALAT1 interacts with SR proteins and influences the distribution of these and other splicing factors in nuclear speckle domains. 20797886 LncRNADisease
SR proteins RNA-Protein binding MALAT1 interacts with SR proteins and influences the distribution of these and other splicing factors in nuclear speckle domains. 20797886
SR protein family RNA-Protein regulation MALAT1 regulates the expression level, localization, and activity SR proteins. 20864030 LncRNADisease
SRSF1 RNA-Protein regulation Upon MALAT1 depletion, expression of SRSF1 protein is increased. 20864030 LncRNADisease
p54nrb RNA-Protein binding In the current model， NEAT1_2 interacts with core paraspeckle proteins PSF and p54nrb, which recruit PSP1 and NEAT1_1 and other associating molecules to the periphery of paraspeckles. 21444682 LncRNADisease
PSF RNA-Protein binding In the current model， NEAT1_2 interacts with core paraspeckle proteins PSF and p54nrb, which recruit PSP1 and NEAT1_1 and other associating molecules to the periphery of paraspeckles. 21444682 LncRNADisease
Pc2 DNA-Protein regulation methylation/demethylation of Polycomb 2 protein (Pc2) controls relocation of growth-control genes between Polycomb bodies (PcGs) and interchromatin granules (ICGs) in response to growth signals. This movement is the consequence of binding of methylated and unmethylated Pc2 to the ncRNAs TUG1 and MALAT1/NEAT2. 22078878 LncRNADisease
Pc2 DNA-Protein regulation Methylation/demethylation of Polycomb 2 protein (Pc2) controls relocation of growth-control genes between Polycomb bodies (PcGs) and interchromatin granules (ICGs) in response to growth signals. This movement is the consequence of binding of methylated and unmethylated Pc2 to the ncRNAs TUG1 and MALAT1/NEAT2. 22078878 LncRNADisease
RNPS1 RNA-Protein regulation RNAi-mediated repression of the nuclear speckle proteins, RNPS1, SRm160, or IBP160, which are well-known mRNA processing factors, resulted in the diffusion of MALAT-1 to the nucleoplasm. 22355166 LncRNADisease
SRm160 RNA-Protein regulation RNAi-mediated repression of the nuclear speckle proteins, RNPS1, SRm160, or IBP160, which are well-known mRNA processing factors, resulted in the diffusion of MALAT-2 to the nucleoplasm. 22355166 LncRNADisease
IBP160 RNA-Protein regulation RNAi-mediated repression of the nuclear speckle proteins, RNPS1, SRm160, or IBP160, which are well-known mRNA processing factors, resulted in the diffusion of MALAT-3 to the nucleoplasm. 22355166 LncRNADisease
pre-mRNA splicing factors RNA-Protein regulation MALAT1 interacts with pre-mRNA splicing factors and regulates cancer cell migration, synapse formation, cell cycle progression, and responses to serum stimulation. 23698766
Bcl-2 RNA-DNA regulation An interaction of Bcl-2 with MALAT-1 lncRNA expression was revealed. 25036876
Sp1 and LTBP3 promoter RNA-DNA binding lncRNA MALAT1 directly interacted with Sp1 and LTBP3 promoterto increase expression of LTBP3 gene. 25187517
Cisplatin and paclitaxel N/A regulation Cisplatin and paclitaxel have target function on significant lncRNAs in LSCC, which presents novel molecular targets to cure LSCC patients and also leads an orientation for developing new drugs. 25257554
SiRNA RNA-RNA regulation SiRNA knockdown of HOTAIR in GC cells significantly inhibited cell proliferation 25280565
PI3K/AKT signaling pathway RNA-Protein regulation MALAT1 might suppress the tumor growth and metastasis via I3K/AKT signaling pathway. 25431257
miR-101 and miR-217 RNA-RNA regulation A significant negative correlation exists between miR-101 or miR-217 and MALAT1 in 42 pairs of ESCC tissue samples and adjacent normal tissues. 25538231
CCL5 RNA-Protein regulation The stimulation of colon cancer progression by TADC-derived CCL5 was associated with the up-regulation of non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1), which subsequently increased the expression of Snail. 25546229
ATM-CHK2 pathway RNA-Protein regulation Western-blotting results implicated that the ATM-CHK2 pathway which is associated with G2/M arrest was phosphorylated by MALAT1 knockdown. 25613496
RANKL RNA-Protein regulation We found that RANKL induced the expression of a lncRNA, MALAT1, for the first time. Knockdown of RANK by siRNA blocked the induction of MALAT1 by RANKL. In addition, MALAT1 also regulated OPG expression in hFOB 1.19 cells. 25817340
PI3K-AKT pathway N/A regulation Downregulation of long noncoding RNA MALAT1 induces epithelial-to-mesenchymal transition via the PI3K-AKT pathway in breast cancer. 26191181
miRNA-124 RNA-RNA regulation Knockdown of MALAT1 increased the expression of miRNA-124. MALAT1 can indirectly modulate GRB2 expression via competing miR-124. 26242259
TDP-43 RNA-Protein binding TDP-43 directly bound to MALAT1 RNA. Silencing TDP-43 expression effectively decreased MALAT1 RNA transcript level. In contrast, TDP-43 overexpression markedly increased MALAT1 transcript level. 26265046
hsa-miR-1 RNA-RNA regulation MiR-1 functioned as a tumor suppressor by targeting K-RAS and MALAT1. 26275461
miR-145 RNA-RNA regulation miR-145 and MALAT1 were in the same Ago2 complex and there was a reciprocal repression between them. 26311052
Sp1/3 DNA-Protein regulation Co-silencing of Sp1 and Sp3 synergistically repressed MALAT1 expression. Sp1 binding inhibitor, mithramycin A (MIT), also inhibited MALAT1 expression in HCC cells. 26352013
EZH2 (enhancer of zeste homolog 2) and H3K27me3 RNA-Protein regulation Knockdown of MALAT1 reversed CSE-induced increases of EZH2 (enhancer of zeste homolog 2) and H3K27me3 levels. In addition to the alteration from epithelial to spindle-like mesenchymal morphology, chronic exposure of HBE cells to CSE increased the levels of EZH2, H3K27me3, vimentin, and N-cadherin and decreased E-cadherin levels, effects that were reversed by MALAT1 siRNA or EZH2 siRNA. 26415832
miR-217 DNA-RNA regulation Over-expression of miR-217 with a mimic attenuated the CSE-induced increase of MALAT1 levels, and reduction of miR-217 levels by an inhibitor enhanced expression of MALAT1. MiR-217 regulation of EZH2/H3K27me3 via MALAT1 is involved in CSE-induced EMT and malignant transformation of HBE cells. 26415832
miR-200s RNA-RNA binding MALAT1 promote KIRC proliferation and metastasis through sponging miR-200s in vitro and in vivo. 26461224
miR-1 RNA-RNA regulation There was reciprocal repression between MALAT1 and miR-1, and slug was identified as a downstream target of miR-1. 26482776
EZH2 RNA-Protein binding EZH2 binds to MALAT1.The 3' end of MALAT1 interacts with the N-terminal of EZH2. 26516927
N-cadherin, Vimentin, E-cadherin RNA-Protein regulation MALAT1 knockdown significantly suppressed N-cadherin and Vimentin expression but induced E-cadherin expression in vitro. 26522444
ZO-1, occludin and claudin-5 RNA-Protein regulation Knockdown of MALAT1 resulted in an impairment and increased the permeability of BTB as well as decreased the expression of ZO-1, occludin and claudin-5 in GECs. 26619802
miR-140 RNA-RNA regulation There was reciprocal repression between MALAT1 and miR-140, and miR-140 mediated the effects that MALAT1 knockdown exerted. 26619802
ERK/MAPK signaling N/A regulation Downregulation of MALAT1 could activate ERK/MAPK signaling and promoted proliferation in SHG139 cells. 26649728
Sox2 and Nestin RNA-Protein regulation Downregulation of MALAT1 suppressed the expression of Sox2 and Nestin which are related to stemness. 26649728
Hsa-miR-1 RNA-RNA regulation A reciprocal negative control relationship between MALAT1 and miR-1. 26676637
pro-apoptotic proteins including cleaved caspase-3, cleaved caspase-9 and cleaved poly (ADP-ribose) polymerase-1 (PARP-1). RNA-Protein regulation Reduced expression of MALAT-1 by RNA interference resulted in enhanced apoptosis in JEG-3 cells, accompanied with elevated levels of the pro-apoptotic proteins including cleaved caspase-3, cleaved caspase-9 and cleaved poly (ADP-ribose) polymerase-1 (PARP-1). 26722461
PCDH10 RNA-DNA regulation Long noncoding RNA (lncRNA) MALAT1 binds EZH2, suppresses the tumor suppressor PCDH10, and promotes gastric cellular migration and invasion. 26871474
EZH2 RNA-Protein binding Long noncoding RNA (lncRNA) MALAT1 binds EZH2, suppresses the tumor suppressor PCDH10, and promotes gastric cellular migration and invasion. 26871474
miR-124 RNA-RNA binding MALAT1 acted as an endogenous potent regulator by directly binding to miR-124 and down-regulating miR-124 expression. 26918449
cyclin-dependent kinase 4 (CDK4) RNA-DNA regulation MALAT1 reversed the inhibitory effect of miR-124 on breast cancer proliferation and was involved in the cyclin-dependent kinase 4 (CDK4) expression. 26918449
cdc42 RNA-DNA regulation MALAT1 regulated migration and invasion of breast cancer cells via affecting cdc42 through binding miR-1 competitively. miR-1 bound both MALAT1 and cdc42 3'UTR directly. 26926567
miR-1 RNA-RNA binding MALAT1 regulated migration and invasion of breast cancer cells via affecting cdc42 through binding miR-1 competitively. 26926567